Percutaneous coronary intervention in the elderly

Nature Reviews Cardiology

Volumn 8, Issue 2, 2011, Pages 79-90

  Wang, Tracy Y ^a   Gutierrez, Antonio ^a   Peterson, Eric D ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; ELDERLY CARE; HEALTH CARE PERSONNEL; HEART MUSCLE ISCHEMIA; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; REVIEW; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; CORONARY DISEASE; HUMANS;

EID: 79451471014     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.184     Document Type: Review

References (117)

1. Alexander, K. P et al. for the CRUSADE Investigators. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J. Am. Coll. Cardiol. 46, 1479-1487 (2005).
2. Mehta, R. H. et al. Acute myocardial infarction in the elderly: differences by age. J. Am. Coll. Cardiol. 38, 736-741 (2001).
3. Anderson, J. L. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol. 50, e1-e157 (2007).
4. Antman, E. M. et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 117, 296-329 (2008).
5. From, A. M., Rihal, C. S., Lennon, R. J., Holmes, D. R. Jr & Prasad, A. Temporal trends and improved outcomes of percutaneous coronary revascularization in nonagenarians. JACC Cardiovasc. Interv. 1, 692-698 (2008).
6. Singh, M. et al. Trends in the association between age and in-hospital mortality after percutaneous coronary intervention: National Cardiovascular Data Registry experience. Circ. Cardiovasc. Interv. 2, 20-26 (2009).
7. Bauer, T. et al. Predictors of hospital mortality In the elderly undergoing percutaneous coronary intervention for acute coronary syndromes and stable angina. Int. J. Cardiol. doi:10.1016/j.ijcard.2010.05.006.
8. Kelsey, S. F et al. Results of percutaneous transluminal coronary angioplasty in patients ≥65 years of age (from the 1985 to 1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry). Am. J. Cardiol. 66, 1033-1038 (1990).
9. Rizo-Patron, C., Hamad, N., Paulus, R., Garcia, J. & Beard, E. Percutaneous transluminal coronary angioplasty in octogenarians with unstable coronary syndromes. Am. J. Cardiol. 66, 857-858 (1990).
10. Newman, A. B. et al. Coronary artery calcification in older adults to age 99: prevalence and risk factors. Circulation 104, 2679-2684 (2001).
11. Sangiorgi, G. et al. Arterial calcification and not Umen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology J. Am. Coll. Cardiol. 31, 126-133 (1998).
12. Hsu, J. T., Kyo, E., Chu, C. M., Tsuji, T & Watanabe, S. Impact of calcification length ratio on the intervention for chronic total occlusions. Int. J. Cardiol. doi:10.1016/j.ijcard.2010.03.002.
13. Soon, K. H. et al. CT coronary angiography predicts the outcome of percutaneous coronary intervention of chronic total occlusion. J. Interv. Cardiol. 20, 359-366 (2007).
14. De Felice, F et al. Clinical outcome of patients with chronic total occlusion treated with drug-eluting stents. Int. J. Cardiol. 132, 337-341 (2009).
15. Hsu, J. T, Tamai, H., Kyo, E., Tsuji, T. & Watanabe, S. Traditional antegrade approach versus combined antegrade and retrograde approach in the percutaneous treatment of coronary chronic total occlusions. Catheter. Cardiovasc. Interv. 74, 555-563 (2009).
16. Batchelor, W. B. et al. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. J. Am. Coll. Cardiol. 36, 723-730 (2000).
17. Scheubel, R. J. et al. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J. Am. Coll. Cardiol. 42, 2073-2080 (2003).
18. Heiss, C. et al. Impaired progenitor cell activity in age-related endothelial dysfunction. J. Am. Coll. Cardiol. 45, 1441-1448 (2005).
19. Hill, J. M. et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348, 593-600 (2003).
20. Becker, R. C. Thrombotic preparedness in aging: a translatable construct for thrombophilias? J. Thromb. Thrombolysis 24, 323-325 (2007).
21. Lopes, R. D. & Alexander, K. P Antiplatelet therapy in older adults with non-ST-segment elevation acute coronary syndrome: considering risks and benefits. Am. J. Cardiol. 104 (Suppl. 5), 16C-21C (2009).
22. Balleisen, L., Bailey, J., Epping, P H., Schulte, H. & van de Loo, J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb. Haemost. 54, 475-479 (1985).
23. Mari, D. et al. Hypercoagulability in centenarians: the paradox of successful aging. Blood 85, 3144-3149 (1995).
24. Zahavi, J., Jones, N. A., Leyton, J., Dubiel, M. & Kakkar, V. V. Enhanced in vivo platelet "release reaction" in old healthy individuals. Thromb. Res. 17, 329-336 (1980).
25. Terres, W., Weber, K., Kupper, W. & Bleifeld, W. Age, cardiovascular risk factors and coronary heart disease as determinants of platelet function in men. A multivariate approach. Thromb. Res. 62, 649-661 (1991).
26. Lakatta, E. G. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 107, 490-497 (2003).
27. Acree, L. S. et al. Age-related influences on markers of inflammation and fibrinolysis [abstract]. FASEB J. 22, 923.7 (2008).
28. Knight, C. J. et al. Altered platelet function detected by flow cytometry. Effects of coronary artery disease and age. Arterioscler. Thromb. Vasc. Biol. 17, 2044-2053 (1997).
29. Vaughan, L., Zurlo, F & Ravussin, E. Aging and energy expenditure. Am. J. Clin. Nutr. 53, 821-825 (1991).
30. Fülöp, T., Jr, Wórum, I., Csongor, J., Fóris, G. & Leövey, A. Body composition in elderly people. I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology 31, 6-14 (1985).
31. Robert, L. Aging of the vascular wall and atherogenesis: role of the elastin-laminin receptor. Atherosclerosis 123, 169-179 (1996).
32. Madhavan, S., Ooi, W. L., Cohen, H. & Alderman, M. H. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 23, 395-401 (1994).
33. Vestal, R. E., Wood, A. J. & Shand, D. G. Reduced ß-adrenoceptor sensitivity in the elderly. Clin. Pharmacol. Ther. 26, 181-186 (1979).
34. Haqqani, H. M. & Kalman, J. M. Aging and sinoatrial node dysfunction: musings on the not-so-funny side. Circulation 115, 1178-1179 (2007).
35. Reinecke, H. et al. Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int. 63, 696-701 (2003).
36. Mehran, R. et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J. Am. Coll. Cardiol. 44, 1393-1399 (2004).
37. Fried, L. P et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 56, M146-M156 (2001).
38. Buchner, D. M. & Wagner, E. H. Preventing frail health. Clin. Geriatr. Med. 8, 1-17 (1992).
39. Afilalo, J., Karunananthan, S., Eisenberg, M. J., Alexander, K. P & Bergman, H. Role of frailty in patients with cardiovascular disease. Am. J. Cardiol. 103, 1616-1621 (2009).
40. Cohen, H. J. In search of the underlying mechanisms of frailty. J. Gerontol. A Biol. Sci. Med. Sci. 55, M706-M708 (2000).
41. Purser, J. L. et al. Identifying frailty in hospitalized older adults with significant coronary artery disease. J. Am. Geriatr. Soc. 54, 1674-1681 (2006).
42. Hlatky, M. A. et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am. J. Cardiol. 64, 651-654 (1989)
43. Working Group on Functional Outcome Measures for Clinical Trials. Functional outcomes for clinical trials in frail older persons: time to be moving. J. Gerontol. A Biol. Sci. Med. Sci. 63, 160-164 (2008).
44. Guralnik, J. M. et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J. Gerontol. A Biol. Sci. Med. Sci. 55, M221-M231 (2000).
45. Walston, J. et al. for the Cardiovascular Health Study. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch. Intern. Med. 162, 2333-2341 (2002).
46. Penninx, B. W. et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J. Am. Geriatr. Soc. 52, 719-724 (2004).
47. Subherwal, S. et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early mplementation of the ACC/AHA Guidelines) Bleeding score. Circulation 119, 1873-1882 (2009).
48. McKellar, S. H., Brown, M. L., Frye, R. L., Schaff, H. V. & Sundt, T. M. 3rd Comparison of coronary revascularization procedures in octogenarians: a systematic review and meta-analysis. Nat Clin. Pract. Cardiovasc. Med. 5, 738-746 (2008).
49. Johnman, C. et al. Percutaneous coronary intervention in the elderly: changes in case-mix and periprocedural outcomes in 31,758 patients treated between 2000 and 2007. Circ. Cardiovasc. Interv. 3, 341-345 (2010).
50. Giugliano, R. P, Lloyd-Jones, D. M., Camargo, C. A., Jr., Makary, M. A. & O'Donnell, C. J. Association of unstable angina guideline care with improved survival. Arch. Intern. Med. 160, 1775-1780 (2000).
51. Bhatt, D. L. et al. for the CRUSADE Investigators. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 292, 2096-2104 (2004).
52. Lakatta, E. G. Changes in cardiovascular function with aging. Eur. Heart J. 11 (Suppl. C), 22-29 (1990).
53. Lakatta, E. Aging effects on the vasculature in health: risk factors for cardiovascular disease. Am. J. Geriatr. Cardiol. 3, 11-17 (1994).
54. Priebe, H. J. The aged cardiovascular risk patient. Br. J. Anaesth. 85, 763-778 (2000).
55. Folkow, B. & Svanborg, A. Physiology of cardiovascular aging. Physiol. Rev. 73, 725-764 (1993).
56. [No authors listed] Coronary Artery Surgery Study (CASS): a randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. Circulation 68, 951-960 (1983).
57. [No authors listed] Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N. Engl. J. Med. 335, 217-225 (1996).
58. Lee, P Y., Alexander, K. P, Hammill, B. G., Pasquali, S. K. & Peterson, E. D. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 286, 708-713 (2001).
59. [No authors listed] A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N. Engl. J. Med. 336, 1621-1628 (1997).
60. De Boer, M. J. et al. for the Myocardial Infarction Study Group. Reperfusion therapy in elderly patients with acute myocardial infarction: A randomized comparison of primary angioplasty and thrombolytic therapy. J. Am. Coll. Cardiol. 39, 1723-1728 (2002).
61. Goldenberg, I. et al. Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction. Am. Heart J. 145, 862-867 (2003)
62. th Annual Transcatheter Cardiovascular Therapeutics Symposium, October 16-21, 2005.
63. De Boer, S. P et al. for the PCAT-2 Trialists Collaborators Group. Mortality and morbidity reduction by primary percutaneous coronary intervention is independent of the patient's age. JACC Cardiovasc. Interv. 3, 324-331 (2010).
64. Mehta, R. H. et al. for the GRACE Investigators. Effectiveness of primary percutaneous coronary intervention compared with that of thrombolytic therapy in elderly patients with acute myocardial infarction. Am. Heart J. 147, 253-259 (2004).
65. Tiefenbrunn, A. J., Chandra, N. C., French, W. J., Gore, J. M. & Rogers, W. J. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J. Am. Coll. Cardiol. 31, 1240-1245 (1998).
66. Thiemann, D. R. et al. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 101, 2239-2246 (2000).
67. Antman, E. M. et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 284, 835-842 (2000).
68. Eagle, K. A. et al. for the GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 291, 2727-2733 (2004).
69. Bach, R. G. et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann. Intern. Med. 141, 186-195 (2004).
70. Gore, J. M. et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 92, 2811-2818 (1995).
71. Boden, W. E. et al. for the COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356, 1503-1516 (2007).
72. Shaw, L. J. et al. for the COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117, 1283-1291 (2008).
73. Weintraub, W. S. et al. for the COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N. Engl. J. Med. 359, 677-687 (2008).
74. TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): A randomised trial. Lancet 358, 951-957 (2001).
75. Pfisterer, M. et al. for the TIME Investigators. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 289, 1117-1123 (2003).
76. Graham, M. M., Norris, C. M., Galbraith, P. D., Knudtson, M. L. & Ghali, W. A. for the APPROACH Investigators. Quality of life after coronary revascularization in the elderly. Eur. Heart J. 27, 1690-1698 (2006).
77. Singh, M. et al. Frailty and its potential relevance to cardiovascular care. Mayo Clin. Proc. 83, 1146-1153 (2008).
78. rd edn (Marcel Dekker, New York, 2004).
79. Cheitlin, M. D. et al. Database Conference January 27-30, 2000, Washington DC\Do existing databases answer clinical questions about geriatric cardiovascular disease and stroke? Am. J. Geriatr. Cardiol. 10, 207-223 (2001).
80. Jin, R., Furnary, A. P, Fine, S. C., Blackstone, E. H. & Grunkemeier, G. L. Using Society of Thoracic Surgeons risk models for risk-adjusting cardiac surgery results. Ann. Thorac. Surg. 89, 677-682 (2010).
81. Wilson, M. F., Baig, M. K. & Ashraf, H. Quality of Ife in octagenarians after coronary artery bypass grafting. Am. J. Cardiol. 95, 761-764 (2005).
82. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J. Am. Coll. Cardiol. 49, 1600-1606 (2007).
83. Barsness, G. W. et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 96, 2551-2556 (1997).
84. Serruys, P W. et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J. Am. Coll. Cardiol. 46, 575-581 (2005).
85. Serruys, P W. et al. for the ARTS II Investigators. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J. Am. Coll. Cardiol. 55, 1093-1101 (2010).
86. Hlatky, M. A. et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 373, 1190-1197 (2009).
87. Artinian, N. T., Duggan, C. & Miller, P Age differences in patient recovery patterns following coronary artery bypass surgery. Am. J. Crit Care 2, 453-461 (1993).
88. Peterson, E. D. et al. for the AHA Chronic CAD Working Group. Multicenter experience in revascularization of very elderly patients. Am. Heart J. 148, 486-492 (2004).
89. Newman, M. F. et al. for the Neurological Outcome Research Group and the Cardiothoracic Anesthesiology Research Endeavors Investigators. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N. Engl. J. Med. 344, 395-402 (2001).
90. Slater, J. P et al. Cerebral oxygen desaturation predicts cognitive decline and longer hospital stay after cardiac surgery. Ann. Thorac. Surg. 87, 36-44 (2009).
91. Shroyer, A. L. et al. for the ROOBY Study Group. On-pump versus off-pump coronary-artery bypass surgery. N. Engl. J. Med. 361, 1827-1837 (2009).
92. Kaehler, J., Meinertz, T & Hamm, C. W. Coronary interventions in the elderly. Heart 92, 1167-1171 (2006).
93. PROTECT I, A Prospective Feasibility Trial Investigating the Use of IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI. Clinical trials.gov [online], http://clinicaltrials. gov/ct2/show/NCT00534859 (2010).
94. Arieti, M., Pesarini, G. & Ribichini, F. Percutaneous Impella Recover circulatory support in high-risk coronary angioplasty. Cardiovasc. Revasc. Med. 9, 269-274 (2008).
95. Hybrid Revascularization Observational Study. Clinical trials.gov [online] http://clinicaltrials. gov/ct2/show/NCT01121263 (2010).
96. Groeneveld, P W., Matta, M. A., Greenhut, A. P & Yang, F. Drug-eluting compared with bare-metal coronary stents among elderly patients. J. Am. Coll. Cardiol. 51, 2017-2024 (2008).
97. Douglas, P S. et al. Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J. Am. Coll. Cardiol. 53, 1629-1641 (2009).
98. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent mplantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356, 2037-2044 (2000).
99. Boersma, E. et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359, 189-198 (2002).
100. Hoekstra, J. W. et al. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad. Emerg. Med. 12, 431-438 (2005).
101. Sadeghi, H. M. et al. Percutaneous coronary interventions in octogenarians: glycoprotein IIb/IIa receptor inhibitors' safety profile. J. Am. Coll. Cardiol. 42, 428-432 (2003).
102. Yang, X. et al. for the CRUSADE Investigators. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J. Am. Coll. Cardiol. 46, 1490-1495 (2005).
103. Alexander, K. P et al. for the CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294, 3108-3116 (2005).
104. Alexander, K. P et al. Decline in GP 2b3a inhibitor overdosing with site-specific feedback in CRUSADE [abstract 3527]. Circulation 116 (Suppl. II), 798-799 (2007).
105. Lincoff, A. M. et al. for the REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292, 696-703 (2004).
106. Lopes, R. D. et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J. Am. Coll. Cardiol. 53, 1021-1030 (2009).
107. Lopes, R. D. et al. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC Cardiovasc. Interv. 3, 669-677 (2010).
108. Marso, S. P et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA 303, 2156-2164 (2010).
109. Mehta, S. R. et al. for the CURE Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001).
110. Steinhubl, S. R. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention, a randomized controlled trial (CREDO). JAMA 288, 2411-2420 (2002).
111. Berger, P B. et al. for the CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 121, 2575-2583 (2010).
112. Wiviott, S. D. et al. for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
113. Chin, C. T. et al. for the TRILOGY ACS Steering Committee. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am. Heart J. 160, 16-22.e11 (2010).
114. Wallentin, L. et al. for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
115. 12 Inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am. Heart J. 160, 65-72 (2010).
116. Mehta, S. K. et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ. Cardiovasc. Interv. 2, 222-229 (2009).
117. Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI). Clinical trials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01177592 (2010).